High-Dose Chemotherapy with Stem-Cell Rescue for Pediatric Brain Tumors
Author Information
Author(s): Panosyan Eduard H., Ikeda Alan K., Chang Vivian Y., Laks Dan R., Reeb Charles L., Bowles La Vette, Lasky Joseph L. III, Moore Theodore B.
Primary Institution: UCLA Medical Center, Mattel Children's Hospital, Los Angeles, CA, USA
Hypothesis
Can high-dose chemotherapy with autologous hematopoietic stem-cell rescue improve outcomes for pediatric brain tumor patients?
Conclusion
High-dose chemotherapy with stem-cell rescue shows a limited but definitive role for selected pediatric brain tumors with poor prognosis.
Supporting Evidence
- Three-year progression-free survival was 60.5% ± 16.
- Overall survival probability was 69.3% ± 11.5.
- Patients with complete remissions prior to AHSCR had a 100% survival rate.
Takeaway
This study looked at kids with brain tumors who got strong chemotherapy and stem cells to help them get better. Some kids did really well, but others still had a tough time.
Methodology
Retrospective analysis of clinical outcomes and toxicities in 18 pediatric patients treated with HDCT-AHSCR.
Potential Biases
Potential biases due to the retrospective design and selection of patients.
Limitations
The study's retrospective nature and small sample size limit the statistical power and generalizability of the findings.
Participant Demographics
Patients were aged 0.4 to 19 years, with a male to female ratio of 2:1.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI = 2.67–15.9 for PFS, 95% CI = 1.86–13.4 for OS
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website